G cap-stabilized oligonucleotides

Details G cap-stabilized oligonucleotides G cap-stabilized oligonucleotides

2007-06-12

2007-06-12

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024100, C536S024500, C435S006120, C435S091500

Reexamination Certificate

active

09860784

ABSTRACT:
Oligonucleotides of the formulain-line-formulae description="In-line Formulae" end="lead"?5′-(CAP)-(Oligo)-(CAP)-3′in-line-formulae description="In-line Formulae" end="tail"?are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is Gm, where m is an integer of from zero to ten, the two CAP's which are present in the molecule can be defined independently of each other and must be different in the case where m is zero at the 5′ or 3′ end and the end of the Oligo sequence is other than guanine. The oligonucleotides can be synthesized chemically. The oligonucleotides are used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors.

REFERENCES:
patent: 4514577 (1985-04-01), Filbey et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 6013639 (2000-01-01), Peyman et al.
patent: 6121434 (2000-09-01), Peyman et al.
patent: 2144475 (1995-09-01), None
patent: 0 552 766 (1993-01-01), None
patent: 0 552 766 (1993-07-01), None
Koga et al., “Alternating α, β Oligothymidylates with Alternating (3′→3′) and 5′→5′)-Internucleotidic Phospodiester Linkages as Models for Antisense Oligodeoxyribonucleotides,” Journal of Organic Chemistry, vol. 56, No. 12 pp. 3757-3759, Jun. 1991.
Hughes et al., “Influence of Base Composition on Membrane Binding and Cellular Uptake of 10-mer Phosphorothioate Oligonucleotides in Chinese Hamster Ovary (CHRC5) Cells” Antisense Research and Development 4:211-215, 1994.
Uhlmann et al., “Oligonucleotide Analogs Containing Dephospho-Internucleoside Linkages”, Methods in Molecular Biology, pp. 355-389, 1993.
Vandendriessche et al., “Acylic Oligonucleotides: Possibilities and Limitations”, Tetrahedron vol. 49, No. 33, pp. 7223-7238, 1993.
Bock et al., “Selection of single-stranded DNA molecules that bind and inhibit human 000 thrombin”, Nature vol. 355, pp. 564-566, Feb. 1992.
Castanotto et al., Biological and Funcational Aspects of Catalytic RNAs, Critical Reviews in Eukaryotic Gene Expressions, 2(4): 331-349, (1992).
Mann et al., “Synthesis and Properties of an Oligodeoxynucleotide Modified with a Pyrene Derivative at the 5′-Phosphate”, Bioconjugate Chem., vol. 3. No. 6, pp. 554-558, 1992.
Sawadogo et al., “A rapid method for the purification of deprotected oligodeoxynucleotides”, Nucleic Acids Research, vol. 19, No. 3, pp. 674, 1991.
Manohoran, “Designer Antisense Oligonucleotides: Conjugation Chemistry and Functionality Placement”, Antisense Research and Applications, pp. 303-349, 1993.
Uhlmann et al., “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews, vol. 90, No. 4, pp. 543-584, Jun. 1990.
Milligan et al., “Current Concepts in Antisense Drug Design”, Journal of Medicinal Chemistry, vol. 36, No. 14, pp. 1923-1937, Jul. 9, 1993.
Bielinska et al., “Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides”, Science, vol. 250, pp. 997-1,000, Nov. 1990.
Cooke, “Medicinal Chemistry Strategies for Antisense Research”, Antisense Research and Applications, pp. 149-187, 1993.
Tang et al., “Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and Anti-HIV activity”, Nucleic Acids Research, vol. 21, No. 11, pp. 2729-2735, 1993.
Blackburn, “Structure and function of telomeres”, Nature vol. 350, No. 18, pp. 569-573, Apr. 1991.
Stirchak et al., “Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages”, Nucleic Acids Research vol. 17, No. 15, pp. 6129-6141, 1989.
Nielsen et al., “Peptide Nucleic Acid (PNA). A DNA Mimic with a Peptide Backbone”, Bioconjugate Chem., vol. 5, pp. 3-7, 1994.
Tarkoy et al., Nucleic—Acid Analogues with Constraint Conformational Flexibility in Sugar-Phosphate Backbone (‘Bicyclo-DNA’), Helevetica Chimica Acta, vol. 76, pp. 481-510, 1993.
Froehler, “Triple-Helix Formation by Oligodeoxynucleotides Containing the Carbocyclic Analogs of Thymidine and 5-Methyl-2′-deoxycytidine”, J. Am. Chem. Soc., vol. 114, pp. 8320-8322, 1992.
J. Goodchild, Bioconj, Chem. vol. 1(3): 165-87 ″90.
D. Tidd et al., Brit. J. Cancer 60:343-50 ′89.
T. Maniatis et al., Molecular Cloning a Lab Manual, Cold Spring Harbor Laboratory (′82), pp. 241-242, 390-391.
C. Stein et al., Science 261: 1004-12 ′93.
B. Tseng et al., Cancer G. Therapy 1 (1): 65-71 ′94.
R. Still et al., Pharm. Res. 12 (4) 465-83 ′95.

Affiliated with

Also associated with

Rating

G cap-stabilized oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with G cap-stabilized oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and G cap-stabilized oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3831980